Nuzenio

Tradingview Spyre Therapeutics

Tradingview Spyre Therapeutics entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 7 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Price to sales forward of Spyre Therapeutics, Inc – DUS:3920 - TradingViewTradingView · Fri, 07 Aug 2026 05:38:06 GMTSpyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside - TradingViewTradingView · Wed, 05 Aug 2026 17:20:17 GMTSpyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Tue, 04 Aug 2026 21:21:22 GMTSpyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026 - TradingViewTradingView · Tue, 04 Aug 2026 20:14:03 GMTSpyre Therapeutics reports $1.145B cash, Q2 net loss $36.2M; positive Phase 2 induction data - TradingViewTradingView · Tue, 04 Aug 2026 20:13:01 GMTSpyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary - TradingViewTradingView · Tue, 04 Aug 2026 20:11:01 GMTSYRE: Strong liquidity and key clinical milestones support ongoing R&D despite rising losses - TradingViewTradingView · Tue, 04 Aug 2026 20:04:13 GMT

Timeline

Fri, 07 Aug 2026 05:38:06 GMTPrice to sales forward of Spyre Therapeutics, Inc – DUS:3920 - TradingView
Wed, 05 Aug 2026 17:20:17 GMTSpyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside - TradingView
Tue, 04 Aug 2026 21:21:22 GMTSpyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Tue, 04 Aug 2026 20:14:03 GMTSpyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026 - TradingView
Tue, 04 Aug 2026 20:13:01 GMTSpyre Therapeutics reports $1.145B cash, Q2 net loss $36.2M; positive Phase 2 induction data - TradingView
Tue, 04 Aug 2026 20:11:01 GMTSpyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Spyre Therapeutics.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.